{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:56:46Z","timestamp":1774573006038,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","valueinhealthjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jval.2024.07.008","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T17:58:26Z","timestamp":1722448706000},"page":"1641-1647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Discriminatory Properties of the Quality-Adjusted Life Year Based Cost-Effectiveness Analyses for Patients With Disabilities: A\u00a0Duchenne\u00a0Muscular Dystrophy Case Study"],"prefix":"10.1016","volume":"27","author":[{"given":"Alexa C.","family":"Klimchak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren E.","family":"Sedita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor M.","family":"Perfetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine L.","family":"Gooch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.","family":"Malone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jval.2024.07.008_bib1","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1377\/hlthaff.2021.00343","article-title":"Controversy over using quality-adjusted life-years in cost-effectiveness analyses: a systematic literature review","volume":"40","author":"Rand","year":"2021","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"10.1016\/j.jval.2024.07.008_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40273-014-0216-0","article-title":"Validation of the underlying assumptions of the quality-adjusted life-years outcome: results from the echoutcome European project","volume":"33","author":"Beresniak","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.jval.2024.07.008_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/jme.13.3.117","article-title":"QALYfying the value of life","volume":"13","author":"Harris","year":"1987","journal-title":"J\u00a0Med Ethics"},{"issue":"4","key":"10.1016\/j.jval.2024.07.008_bib5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/jme.17.4.185","article-title":"Unprincipled QALYs: a response to Cubbon","volume":"17","author":"Harris","year":"1991","journal-title":"J\u00a0Med Ethics"},{"issue":"2","key":"10.1016\/j.jval.2024.07.008_bib6","first-page":"304","article-title":"Why the coming debate over the QALY and disability will be different","volume":"47","author":"Pearson","year":"2019","journal-title":"J\u00a0Law Med Ethics"},{"key":"10.1016\/j.jval.2024.07.008_bib7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1477-7525-1-80","article-title":"Problems and solutions in calculating quality-adjusted life years (QALYs)","volume":"1","author":"Prieto","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"10.1016\/j.jval.2024.07.008_bib8","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s40273-015-0295-6","article-title":"Can the EQ-5D detect meaningful change? A systematic review","volume":"33","author":"Payakachat","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.jval.2024.07.008_bib9","first-page":"689","article-title":"Quality-adjusted life-years, quality-adjusted life-year-like measures, or neither? The debate continues","volume":"27","author":"Devlin","year":"2024","journal-title":"Value Health"},{"issue":"3-4","key":"10.1016\/j.jval.2024.07.008_bib10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1467-8519.1995.tb00368.x","article-title":"Is the sanctity of life ethic terminally ill?","volume":"9","author":"Singer","year":"1995","journal-title":"Bioethics"},{"issue":"6","key":"10.1016\/j.jval.2024.07.008_bib11","first-page":"702","article-title":"The value of the quality-adjusted life years","volume":"27","author":"Willke","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2024.07.008_bib12","author":"Burns"},{"issue":"2","key":"10.1016\/j.jval.2024.07.008_bib13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jval.2020.10.003","article-title":"Health technology assessment with diminishing returns to health: the generalized risk-adjusted cost-effectiveness (GRACE) approach","volume":"24","author":"Lakdawalla","year":"2021","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2024.07.008_bib17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13023-018-0936-x","article-title":"From scientific discovery to treatments for rare diseases - the view from the National Center for Advancing Translational Sciences - Office of Rare Diseases Research","volume":"13","author":"Kaufmann","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"10.1016\/j.jval.2024.07.008_bib18","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/s41436-021-01241-7","article-title":"Can you hear us now? The impact of health-care utilization by rare disease patients in the United States","volume":"23","author":"Navarrete-Opazo","year":"2021","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.jval.2024.07.008_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S2213-8587(19)30006-3","article-title":"Spotlight on rare diseases","volume":"7","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.jval.2024.07.008_bib21","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13023-022-02343-4","article-title":"Healthcare access, satisfaction, and health-related quality of life among children and adults with rare diseases","volume":"17","author":"Bogart","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.jval.2024.07.008_bib22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.jval.2024.07.008_bib23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s11136-019-02355-x","article-title":"Characterizing health state utilities associated with Duchenne muscular dystrophy: a systematic review","volume":"29","author":"Szabo","year":"2020","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.jval.2024.07.008_bib24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jval.2018.12.001","article-title":"Future directions in valuing benefits for\u00a0estimating QALYs: is time up for the EQ-5D?","volume":"22","author":"Brazier","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2024.07.008_bib25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1477-7525-1-54","article-title":"The Health Utilities Index (HUI): concepts, measurement properties and applications","volume":"1","author":"Horsman","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.jval.2024.07.008_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12955-022-02001-0","article-title":"Factors associated with the health-related quality of life among people with Duchenne muscular dystrophy: a study using the Health Utilities Index (HUI)","volume":"20","author":"Szabo","year":"2022","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2024.07.008_bib27","doi-asserted-by":"crossref","first-page":"S574","DOI":"10.1016\/j.jval.2022.04.1519","article-title":"PCR176 time trade-off utility values for health states characterizing progressive muscular degeneration in Duchenne muscular dystrophy (DMD)","volume":"25","author":"Audhya","year":"2022","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2024.07.008_bib28","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s41687-023-00671-y","article-title":"Estimating health state utilities in Duchenne muscular dystrophy using the health utilities index and EQ-5D-5L","volume":"7","author":"Audhya","year":"2023","journal-title":"J\u00a0Patient Rep Outcomes"},{"issue":"Suppl 1","key":"10.1016\/j.jval.2024.07.008_bib29","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1016\/j.jval.2020.04.1307","article-title":"PRO86 health state utility values for stages of functional decline in Duchenne muscular dystrophy: an international study","volume":"23","author":"Crossnohere","year":"2020","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2024.07.008_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/0272989X20978390","article-title":"Assessing the appropriateness of the EQ-5D for Duchenne muscular dystrophy: a patient-centered study","volume":"41","author":"Crossnohere","year":"2021","journal-title":"Med Decis Mak"},{"issue":"6","key":"10.1016\/j.jval.2024.07.008_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2023.03.2772","article-title":"PCR230 estimating utility values using the Duchenne muscular dystrophy-quality of life measure (DMD-QoL): a new preference-based measure for Duchenne muscular dystrophy","volume":"26","author":"Bever","year":"2023","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jval.2024.07.008_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135672","article-title":"Measuring health utilities in children and adolescents: a systematic review of the literature","volume":"10","author":"Thorrington","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jval.2024.07.008_bib33","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.apmr.2006.12.032","article-title":"Response shift theory: important implications for measuring quality of life in people with disability","volume":"88","author":"Schwartz","year":"2007","journal-title":"Arch Phys Med Rehabil"},{"issue":"1","key":"10.1016\/j.jval.2024.07.008_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jpeds.2009.03.007","article-title":"Current challenges and future research in measuring preferences for pediatric health outcomes","volume":"155","author":"Prosser","year":"2009","journal-title":"J\u00a0Pediatr"},{"issue":"1","key":"10.1016\/j.jval.2024.07.008_bib35","first-page":"888","article-title":"QALYs and ambulatory status: societal preferences for healthcare decision making","volume":"25","author":"Freath","year":"2022","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.jval.2024.07.008_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/(SICI)1099-1050(199902)8:1<25::AID-HEC398>3.0.CO;2-H","article-title":"Incorporating societal concerns for fairness in numerical valuations of health programmes","volume":"8","author":"Nord","year":"1999","journal-title":"Health Econ"},{"issue":"3","key":"10.1016\/j.jval.2024.07.008_bib39","first-page":"257","article-title":"Examining US commercial health plans\u2019 use of the Institute for Clinical and Economic Review\u2019s reports in specialty drug coverage decisions","volume":"29","author":"Chambers","year":"2023","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"12","key":"10.1016\/j.jval.2024.07.008_bib40","first-page":"1548","article-title":"HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications","volume":"26","author":"Kruzikas","year":"2020","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"6","key":"10.1016\/j.jval.2024.07.008_bib41","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1212\/WNL.0000000000000669","article-title":"The burden of Duchenne muscular dystrophy: an international, cross-sectional study","volume":"83","author":"Landfeldt","year":"2014","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jval.2024.07.008_bib43","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jval.2024.07.008_bib45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13023-022-02283-z","article-title":"Assessing the value of orphan drugs using conventional cost-effectiveness analysis: is it fit for purpose?","volume":"17","author":"Postma","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"10.1016\/j.jval.2024.07.008_bib46","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","article-title":"United States valuation of EQ-5D-5L health states using an international protocol","volume":"22","author":"Pickard","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2024.07.008_bib47","series-title":"Assessing Technologies That Are Not Cost-Effective at a Zero Price","author":"Davis","year":"2014"},{"issue":"2","key":"10.1016\/j.jval.2024.07.008_bib55","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","article-title":"Defining elements of value in health care-a health economics approach: an ISPOR special task force report [3]","volume":"21","author":"Lakdawalla","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2024.07.008_bib49","series-title":"Presented at the Muscular Dystrophy Association (MDA) Conference","article-title":"Study to Understand the Duchenne Muscular Dystrophy Experience From the Caregiver\/Patient Perspective","author":"Brown","year":"2022"},{"issue":"4","key":"10.1016\/j.jval.2024.07.008_bib50","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s43441-022-00389-x","article-title":"Unmet therapeutic needs of non-ambulatory patients with Duchenne muscular dystrophy: a mixed-method analysis","volume":"56","author":"Schuster","year":"2022","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.jval.2024.07.008_bib51","author":"Smith"},{"issue":"10","key":"10.1016\/j.jval.2024.07.008_bib52","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40273-020-00942-2","article-title":"Perspective and costing in cost-effectiveness analysis, 1974-2018","volume":"38","author":"Kim","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2024.07.008_bib53","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1016\/j.jval.2021.04.903","article-title":"PNS48 do US commercial health plans cite ICER reports in their specialty drug coverage policies? an empirical analysis","volume":"24","author":"Enright","year":"2021","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2024.07.008_bib54","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-022-02182-3","article-title":"Patients\u2019 access to rare neuromuscular disease therapies varies across US private insurers","volume":"17","author":"Margaretos","year":"2022","journal-title":"Orphanet J Rare Dis"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152402789X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152402789X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T08:46:03Z","timestamp":1733129163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109830152402789X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S109830152402789X"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2024.07.008","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discriminatory Properties of the Quality-Adjusted Life Year Based Cost-Effectiveness Analyses for Patients With Disabilities: A\u00a0Duchenne\u00a0Muscular Dystrophy Case Study","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2024.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}